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This work characterized a key function of Sirtuin 6 (SIRT6)
in the regulation of liver fibrosis. Mechanistically, SIRT6
deacetylates and suppresses SMAD family member 3 in
hepatic stellate cells. Gain- and loss-of-function data show
that SIRT6 is a potential therapeutic target for hepatic
fibrosis.
BACKGROUND & AIMS: Nonalcoholic steatohepatitis (NASH) is
a chronic liver disease that is manifested clinically by an in-
crease in hepatic triglycerides, inflammation, and fibrosis. The
pathogenesis of NASH remains incompletely understood. Sir-
tuin 6 (Sirt6), a nicotinamide adenine dinucleotide–dependent
deacetylase, has been implicated in fatty liver disease; howev-
er, the underlying molecular mechanisms in the NASH patho-
genesis are elusive. The aims of this study were to elucidate the
role of hepatic Sirt6 in NASH.
METHODS: Wild-type, liver-specific Sirt6 knockout (KO), he-
patic stellate cell (HSC)-specific Sirt6 knockout (HSC-KO), and
Sirt6 transgenic mice were subjected to a Western diet for 4weeks. Hepatic phenotypes were characterized and underlying
mechanisms were investigated.
RESULTS: Remarkably, both the liver-KO and HSC-KO mice
developed much worse NASH than the wild-type mice, whereas
the transgenic mice were protected from the diet-induced
NASH. Our cell signaling analysis showed that Sirt6 negatively
regulates the transforming growth factor b–Smad family
member 3 (Smad3) pathway. Biochemical analysis showed a
physical interaction between Sirt6 and Smad3 in hepatic stel-
late cells. Moreover, our molecular data further showed that
Sirt6 deacetylated Smad3 at key lysine residues K333 and
K378, and attenuated its transcriptional activity induced by
transforming growth factor b in hepatic stellate cells.
CONCLUSIONS: Our data suggest that SIRT6 plays a critical role
in the protection against NASH development and it may serve
as a potential therapeutic target for NASH. (Cell Mol Gastro-
enterol Hepatol 2020;10:341–364; https://doi.org/10.1016/
j.jcmgh.2020.04.005)
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simple steatosis and gradually progresses to nonalcoholic
steatohepatitis (NASH), cirrhosis, and even liver cancer.1
One of the common risk factors for NAFLD is overweight
or obesity. Excessive energy intake is stored as triglycerides
not only in the adipose tissue, but also in the liver and other
tissues. Hepatic lipid accumulation can cause liver injury
and cellular function impairment by an increase in reactive
oxygen species, endoplasmic reticulum stress, and other
tissue damage responses.2 Hepatic tissue injury also triggers
immune responses including the recruitment of circulated
and resident macrophages and neutrophils, which lead to
inflammation in the liver. Under the inflammatory condi-
tions, hepatic cells secrete various cytokines and chemo-
kines including transforming growth factor b (TGFb) and
chemokine (C-C motif) ligands 2 and 5. TGFb is a potent
fibrogenic factor that can trigger the activation of quiescent
hepatic stellate cells (HSCs).3 On TGFb binding to its re-
ceptors 1/2, the receptor kinase phosphorylates and acti-
vates SMAD2 and SMAD3 transcription factors. Either SMAD
family member 2 (SMAD2) or SMAD3 can form hetero-
dimers with SMAD4 and then translocate to the nucleus for
activation of numerous target genes including fibrogenesis
genes such as ACTA2, COL1A1, and COL3A1.4 In addition to
phosphorylation, SMAD3 also is regulated positively by
lysine acetylation, especially at lysine 378.5
It is believed that interactions between environmental
factors such as diet and epigenetics play an important role
in the development of NAFLD.1 As a key epigenetic regu-
lator, sirtuin 6 (SIRT6) has been implicated in the control of
glucose and lipid metabolism, anti-oxidative stress, and anti-
inflammation.6–16 SIRT6 is a nicotinamide adenine
dinucleotide–dependent deacetylase/deacylase.17–19 Sirt6
deficiency in mice leads to hepatic steatosis and inflamma-
tion.14,20–22 In addition, Sirt6 whole-body knockout mice
develop fibrosis in the heart, liver, kidneys, and lungs.21,23 It
has been suggested that regulation of the TGFb–SMAD2/3
pathway by SIRT6 plays a role in tissue fibrosis.23–25
However, the function and mechanism of SIRT6 in hepatic
stellate cells remains unclear. In this work, we set out to
illustrate the pathophysiological function of Sirt6 in mouse
and human HSCs.*Authors share co-first authorship.
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Hepatic SIRT6 Is Decreased in NASH Patients
and Diet-Induced NASH Mice
To examine the role of SIRT6 in human NASH patho-
genesis, we analyzed hepatic SIRT6 protein levels in con-
trols and patients with NASH. Hepatic SIRT6 was decreased
by 3-fold in those with NASH compared with controls
(Figure 1A), suggesting that SIRT6 might be involved in
human NASH pathogenesis. To further examine whether
SIRT6 is decreased progressively during fibrogenesis, we
stained SIRT6 in liver biopsy specimens from NASH patients
with different stages of NASH progression from simple
steatosis to different degrees of hepatic fibrosis and
cirrhosis. Our data showed that as the disease advanced tofibrosis and cirrhosis, nuclear SIRT6 levels were reduced
markedly (Figure 1B), suggesting a potential role of SIRT6 in
liver fibrosis. We also determined SIRT6 transcript levels by
real-time polymerase chain reaction (PCR) analysis and
found a significant decrease in hepatic SIRT6 messenger
RNA (mRNA) levels in NASH patients (Figure 1C).
To assess the status of Sirt6 in NASH development in
animal models, we fed wild-type (WT) C57BL6/J mice either
a control or Western diet (WD) for 4 and 8 weeks and
analyzed hepatic Sirt6 and Smad3. Our data showed that a
WD induced a significant increase in hepatic steatosis and
fibrosis at 4 weeks, and more so at 8 weeks (Figure 2A).
Hepatic Sirt6 was decreased significantly and Smad2 and
Smad3 phosphorylation levels were increased in the WD-
treated mice (Figure 2B). Moreover, hepatic Smad3 acety-
lation was increased in the livers of the WD-treated mice
(Figure 2C). These data suggest that hepatic SIRT6 is down-
regulated during NASH development in both human beings
and mice. Because HSCs are critical for hepatic fibrogenesis,
we also examined Sirt6 gene expression during HSC acti-
vation using mouse primary HSCs. Within 5 days of culture,
primary HSCs were activated, as shown by an induction of
Col1a1 and Acta2 genes. During the same time course, Sirt6
was decreased at both mRNA and protein levels
(Figure 3A–D). In addition, Sirt6 mRNA levels also were
decreased in the TGFb-treated primary HSCs (Figure 3E).
Taken together, our data suggest that Sirt6 might be
involved in HSC activation and liver fibrosis.Hepatic Sirt6 Protects Against Diet-Induced
NASH in Mice
To further investigate the role of Sirt6 in the develop-
ment of NASH, we generated liver-specific Sirt6 knockout
mice (KO; Alb–Cre-mediated) and whole-body Sirt6 trans-
genic (Tg) mice. As shown by Western blot analysis, Sirt6
was ablated specifically in the liver of KO mice and over-
expressed in both the liver and heart in Tg mice (Figure 4A).
To model NASH development, we fed WT, KO, and Tg mice
with a WD for 4 weeks. Although body weight did not
change significantly, liver weight and the liver-to–body
weight ratio were increased remarkably in the KO mice, but
completely normalized in the Tg mice (Figure 4B–G). Liver
morphology showed a typical fatty liver phenotype in the
Figure 1. SIRT6 protein levels are decreased in the livers of NASH patients. (A) Western blot analysis and quantification of
SIRT6 protein in the human liver samples from controls and NASH patients. (B) Immunohistochemical analysis of SIRT6 in
human liver biopsy specimens from patients with simple hepatic steatosis, different grades of fibrosis, and cirrhosis. (C) Real-
time PCR analysis of TIMP1, ACTA2, COL3A1, COL1A1, and SIRT6 in human liver samples from controls and NASH patients
(n¼ 6). Data are presented as means ± SEM. **P < .01 and ***P < .001. ACTN, actinin.
2020 SIRT6 Function in Hepatic Fibrosis 343KO mice and no abnormal appearance in the Tg mice
(Figure 4H). Biochemical analysis of hepatic triglycerides
also showed a 2-fold increase in the KO mice and normali-
zation in the Tg mice (Figure 4I). H&E staining and quan-
tification of liver sections also confirmed that hepatic
steatosis was much worse in the KO mice than in the WT
mice, but normalized in the Tg mice (Figure 5A and B).
To assess hepatic inflammation, we performed immu-
nohistochemistry for F4/80 (a macrophage marker) and
myeloperoxidase (a neutrophil marker). Both markers were
highly increased in the KO livers and nearly normal in the Tg
mice (Figure 5A and B). Real-time PCR analysis showed that
inflammatory cytokine genes including Il1b and Tnf were
increased significantly in the KO livers and decreased
dramatically in the Tg livers compared with the WT livers
(Figure 5C and D). Serum alanine aminotransferase (ALT)
levels were increased by 50% in the KO mice but nearly
normal in the Tg mice compared with the WT mice
(Figure 5E), indicating a protective role of Sirt6 against liver
injury. In addition, liver injury–associated biliary ductular
reaction was worsened in the KO mice compared with the
WT mice (Figure 5F).
To examine hepatic fibrosis, we first performed Sirius
Red staining of liver sections. Our data showed that KO
mice developed much worse fibrosis than the WT mice,
whereas the Tg mice were completely protected against
fibrosis (Figure 6A and B). This fibrosis phenotype was
corroborated by expression of fibrogenesis genesincluding Col1a1, Acta2, Tgfb1, and Tgfbr1 (Figure 6C). To
explore potential mechanisms, we analyzed Smad3 phos-
phorylation and acetylation, indicators of Smad3 activa-
tion. Our data showed that both modifications were
increased in the KO, but decreased in the Tg, livers
(Figure 6D). To examine whether there was any indication
of epithelial–mesenchymal transition, we analyzed 2
common markers in the livers of WT and KO mice. Our
data showed that E-cadherin was decreased by 75% and
vimentin was increased by 4-fold in the KO livers
(Figure 6E), suggesting that Sirt6 deficiency promotes
epithelial–mesenchymal transition in the liver.Sirt6 Deficiency Triggers Inflammation in
Hepatocytes and Fibrogenesis in HSCs
A recent report showed that Alb-Cre is active in both
hepatocytes and HSCs,26 therefore we also analyzed Sirt6
gene deletion in primary hepatocytes and HSCs in our Alb-
Cre–mediated Sirt6 KO mice. Indeed, Alb-Cre led to 70%
Sirt6 ablation in HSCs, whereas it mediated 90% Sirt6
deletion in hepatocytes (Figure 7A and B). Immunofluores-
cent microscopy also confirmed the Sirt6 deletion in HSCs
and hepatocytes (Figure 7C and D). In addition, we also
examined Sirt6 protein in cholangiocytes by staining liver
sections. Our data showed that Sirt6 was depleted in only a
small fraction of cholangiocytes in the KO mice (Figure 7E).
Gene expression analysis in mouse primary hepatocytes and
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Figure 3. Sirt6 is down-regulated during HSC activation. (A–C) Real-time PCR analysis of Col1a1, Acta2, and Sirt6 mRNAs
in mouse primary HSCs after culture for 1–5 days (n ¼ 3). (D) Western blot analysis of Sirt6 in mouse primary HSCs after culture
for 1–5 days. (E) Real-time PCR analysis of Col1a1, Acta2, and Sirt6 mRNAs in mouse primary HSCs in the absence or
presence of TGFb1 (5 ng/mL) for 24 hours (n ¼ 4). Data are presented as means ± SEM. **P < .01 and ***P < .001 vs control.
Actn, actinin; p-Smad, phospho-SMAD family member 2.
2020 SIRT6 Function in Hepatic Fibrosis 345HSCs showed that a number of cytokine and chemokine
genes including Ccl2, Tgfb1, Ccl5, and Tnf were highly
increased in the hepatocytes whereas fibrogenesis genes
such as Col1a1, Col4a1, Timp1, and Tgfb1 were increased
remarkably in the Sirt6-deficient HSCs compared with their
WT counterparts (Figure 8A and B). We also performed co-
culture experiments to test potential interactions between
primary hepatocytes and HSCs. Although Sirt6-deficient
HSCs did not further induce cytokine and chemokine gene
expression in the KO hepatocytes, Sirt6-deficient hepato-
cytes enhanced fibrogenic gene expression in the KO HSCs
(Figure 8C and D).Figure 2. (See previous page). Hepatic Sirt6 is down-regulat
staining, and immunofluorescence analysis of myeloperoxidas
WD-treated mice (4- to 6-month-old males, n ¼ 4). (D) Wester
p-Smad3, and Smad3 in the livers of control and WD-treated m
(Ac-K-Smad3) in the livers of control and WD-treated mice. Da
***P < .001 vs control; #P < .05, and ##P < .01 vs WD_4w.Sirt6 Deficiency in HSCs Increases the
Susceptibility to Diet-Induced NASH in Mice
To investigate the in vivo function of Sirt6 in HSCs, we
generated Sirt6 HSC-KO mice by crossing the floxed Sirt6
mice with a lecithin retinol acyltransferase (Lrat)-Cre line.
Our data showed that Sirt6 was deleted specifically in HSCs,
but not hepatocytes or Kupffer cells (Figure 9A–D).
Although there was no difference in body weight between
WT and HSC-KO mice, both liver weight and liver-to–body
weight ratio were increased significantly in the HSC-KO
mice after 4 weeks of WD feeding (Figure 9E–G). HSC-KO
mice had much worse hepatic inflammation, liver injury,ed during NASH development in mice. (A) H&E, Sirius Red
e (MPO) and quantification of liver sections of control and
n blot and quantification analysis of Sirt6, p-Smad2, Smad2,
ice. (C) Western blot and quantification of Smad3 acetylation
ta are presented as means ± SEM. *P < .05, **P < .01, and
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markers, serum ALT, and HSC gene expression
(Figure 10A–E). We also analyzed Smad3 phosphorylation
in HSC-KO livers and HSCs and observed thatFigure 4. Sirt6 protects the liver from diet-induced hepatic st
KO, and Sirt6-Tg mouse liver and heart tissues. (B and C) Body
mice (n ¼ 5, 4- to 6-month-old males). (D and E) Liver weight me
5). (H) Gross images of livers of WT, Sirt6-KO, and Sirt6-Tg mice
triglyceride (TG) measurements (n ¼ 4). Data are presented as m
control for the same genotype; #P < .05, ##P < .01, and ###P <phosphorylated Smad3 levels were increased remarkably
(Figure 10F). Fluorescent microscopy also confirmed an
increase in Smad3 phosphorylation and nuclear trans-
location in HSC-KO mouse primary HSCs (Figure 10G).eatosis. (A) Western blot analysis of Sirt6 protein in WT, Sirt6-
weight measurements for Sirt6-KO vs WT and Sirt6-Tg vs WT
asurements (n ¼ 5). (F and G) Liver-to-body weight ratios (n ¼
fed with WD for 4 weeks (4- to 6-month-old males). (I) Hepatic
eans ± SEM. *P < .05, **P < .01, and ***P < .001 for WD vs
.001. Actn, actinin.
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HSCs
To further examine the role of SIRT6 in HSCs, we
selected the human HSC cell line LX-2, which is used
commonly for hepatic fibrosis study. First, we knocked
down the SIRT6 gene in the LX-2 cells using short hairpin
RNAs (shRNAs) and cultured the cells in the absence or
presence of TGFb. Knockdown of SIRT6 significantly
enhanced TGFb-stimulated SMAD3 phosphorylation
(Figure 11A). Second, we performed SIRT6 overexpression
in the LX-2 cells. Western blot data showed that over-
expression of SIRT6 significantly decreased the TGFb-stim-
ulated SMAD3 phosphorylation (Figure 11B). Third, we
overexpressed catalytically inactive SIRT6 mutant (H133Y)
in the LX-2 cells. Our data showed that the TGFb-stimulated
SMAD3 phosphorylation was not decreased by the mutant
SIRT6 (Figure 11E), suggesting that the Sirt6 catalytic ac-
tivity is required for the regulation of SMAD3 phosphory-
lation. Expression of fibrogenic genes including COL1A1,
COL3A1, ACTA2, and TIMP1 in the LX-2 cells also was
consistent with the negative regulation of SMAD3 by SIRT6.
Wild-type but not mutant SIRT6 overexpression repressed
those fibrogenesis genes whereas SIRT6 knockdown
enhanced their expression (Figure 11C, D, and F).
To further understand the molecular regulation of
SMAD3 by SIRT6, we performed co-immunoprecipitation
using either SIRT6 or phosphorylated SMAD3 antibodies.
Our data showed that SIRT6 indeed interacted with both
SMAD3 and its phosphorylated form (Figure 12A and B). We
also performed affinity purification of Sirt6 protein com-
plexes in liver lysates by taking advantage of the HA-tagged
Sirt6 transgene in our Tg mice. Indeed, Sirt6-hemagglutinin
(HA) co-purified with Smad3 and Foxo1 (a positive control)
(Figure 12C). Fluorescent microscopy also showed nuclear
co-localization of SIRT6 and SMAD3, especially after TGFb
stimulation (Figure 12D and E).
To analyze the effect of SIRT6 on SMAD3 acetylation, we
knocked down or overexpressed wild-type or mutant SIRT6
(H133Y) and immunoprecipitated SMAD3 for acetylation
analysis. Our data showed that SIRT6 knockdown increased
SMAD3 acetylation whereas overexpression of WT but not
mutant SIRT6 decreased SMAD3 acetylation (Figure 13A
and B), suggesting that SIRT6 catalytic activity is required
for SMAD3 deacetylation. To verify the interaction between
SIRT6 and SMAD3 in the chromatin context, we performed
chromatin immunoprecipitation (ChIP)–PCR analysis of 2
known SMAD3 target genes: TGFB1 and COL1A2 in LX-2
cells. Our data showed that SIRT6 and acetylated histone
H3 lysine 9 (a substrate of SIRT6) both were enriched in the
SMAD3 binding sites in the TGFB1 and COL1A2 gene pro-
moters (Figure 13C). To further characterize which lysine
acetylation in SMAD3 is regulated by SIRT6, we mutated 2Figure 5. (See previous page). Sirt6 protects against diet-indu
(MPO), and F4/80 staining and quantification analysis of liver se
for 4 weeks (n ¼ 4). (C–E) Hepatic inflammatory gene expression
with a WD for 4 weeks (n¼ 4). (F) Immunostaining and quantifica
with a WD for 4 weeks (n ¼ 4). Data are presented as means ± S
the same genotype; #P < .05, ##P < .01, and ###P < .001. CK-previously reported lysine residues, K333 and K378, to
arginine that cannot be acetylated. Our data showed that
both mutations reduced the SMAD3 acetylation levels and
K378 seemed to be a major deacetylation site by SIRT6
(Figure 13D). Real-time PCR analysis further confirmed that
acetylation of both K333 and K378 was involved in the
SMAD3 transcriptional activity and deacetylation by SIRT6
markedly attenuated the SMAD3 transcriptional activity
(Figure 13E).Discussion
SIRT6 has been implicated in multiple biological pro-
cesses including glucose and lipid metabolism, inflammation,
anti-oxidative stress, DNA repair, and tumor
suppression.6–17,20,22,27–44 In this work, we reported that
SIRT6 is also a key regulator for liverfibrosis. Because NAFLD
is a progressive liver disease, our data suggest that SIRT6 is
involved in nearly all stages of NAFLD pathogenesis: from
steatosis to inflammation and fibrosis. The major finding of
this study is the characterization of the key role of SIRT6 in
the regulation of TGFb–SMAD3 signaling in HSCs. Initially, we
set out to investigate the Sirt6 function in hepatocytes.
Interestingly, our data have shown that Alb–Cre also leads to
the Sirt6 gene deletion in HSCs in addition to hepatocytes,
although not as efficiently as in hepatocytes. Thus, we believe
that the liver phenotype in our Alb–Cre–mediated Sirt6–KO
mice is attributable to Sirt6 deficiency in both hepatocytes
and HSCs. Previously, it has been shown that SIRT6 promotes
hepatic triglyceride homeostasis through inhibition of de
novo lipogenesis and activation of fatty acid oxidation by
histone H3 deacetylation14; however, whether Sirt6 is
deleted or not in HSCs was not examined. SIRT6 also inhibits
cholesterol biosynthesis by repression of the master regu-
lator sterol regulatory element-binding protein 2 (SREBP2)
and its target genes.9 SIRT6 also represses the expression of
the PCSK9 gene to reduce the levels of low-density lipopro-
tein cholesterol.8 Hepatic SIRT6 deficiency leads to increased
cholesterol and triglyceride levels in the blood and liver as
well.8,9 Therefore, hepatic steatosis in Sirt6-KO mice is
attributed mainly to Sirt6 deficiency in hepatocytes. With
regard to liver fibrosis, Sirt6 function in HSCs plays a major
role because the Sirt6 HSC-KO mice develop remarkable he-
patic fibrosis after 4 weeks of Western diet feeding. It has
been reported that the Alb–Cre–mediated Sirt6 KO mice also
developed NASH on a high-fat, high-fructose diet for 16
weeks.20 Sirt6 expression in HSCs was not examined in that
report. The investigators attributed the NASH phenotype in
the Sirt6 KO mice to the antioxidative stress function of Sirt6
by regulation of nuclear factor erythroid 2–related factor 2.20
In this work, we used a different NASH diet that contains 20%
kcal from protein, 40% kcal from carbohydrates (mainly cornced hepatic inflammation. (A and B) H&E, myeloperoxidase
ctions of WT, Sirt6-KO, and Sirt6-Tg male mice fed with a WD
and serum ALT in WT, Sirt6-KO, and Sirt6-Tg male mice fed
tion of CK-19 in the liver sections of WT and Sirt6-KO mice fed
EM. *P < .05, **P < .01, and ***P < .001 for WD vs control for
19, cytokeratin 19.
Figure 6. Sirt6 protects against diet-induced hepatic fibrosis. (A and B) Sirius Red staining of liver sections and quanti-
fication of the positive staining area in the livers of WT, Sirt6-KO, and Sirt6-Tg mice fed with a WD for 4 weeks (n ¼ 4, 4- to 6-
month-old males). (C) Real-time PCR analysis of fibrosis-related genes including Col1a1, Acta2, Tgfb1, and Tgfbr1 in the livers
of WT, Sirt6-KO, and Sirt6-Tg male mice fed with a WD for 4 weeks (n¼ 4). (D) Western blot analysis and quantification of
Smad3, p-Smad3, and acetylated-Smad3 (Ac-K-Smad3) in the livers of WT, Sirt6-KO, and Sirt6-Tg mice. (E) Western blot
analysis and quantification of E-cadherin and vimentin in the livers of WT and Sirt6-KO mice. Data are presented as means ±
SEM. *P < .05, **P < .01, and ***P < .001 for WD vs control for the same genotype; #P < .05, ##P < .01, and ###P < .001. Actn,
actinin; p-Smad, phospho-SMAD family member 2.
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Figure 7. (See previous page). Alb–Cre leads to Sirt6 gene deletion in both hepatocytes and HSCs in the Sirt6f/f:Alb–Cre
mouse liver. (A and B) Western blot and quantification analysis of Sirt6, albumin, and desmin in primary hepatocytes (HEPs)
and HSCs from WT and Sirt6 KO mice induced by either Mx1–Cre or Alb–Cre. (C) Immunofluorescence microscopy analysis of
Sirt6 and albumin in the WT and the Alb–Cre–mediated Sirt6-KO hepatocytes. (D) Immunofluorescence microscopy analysis of
Sirt6 and desmin in the WT and the Alb–Cre–mediated Sirt6-KO HSCs. (E) Immunofluorescence microscopy analysis of Sirt6
and CK-19 in the WT and the Alb–Cre–mediated Sirt6-KO liver sections. Data are presented as means ± SEM. **P < .01 and
***P < .001 vs WT; #P < .05 and ###P < .001 for Alb-Cre KO vs Mx1–Cre KO. Actn, actinin; DAPI, 40,6-diamidino-2-
phenylindole; CK-19, cytokeratin 19.
Figure 8. Gene expression analysis of Sirt6-deficient hepatocytes and HSCs. (A–D) Real-time PCR analysis of selected
genes in monocultured or cocultured hepatocytes (HEPs) and HSCs. Data are presented as means ± SEM. *P < .05, **P < .01,
and ***P < .001 vs WT or WT/WT; #P < .05, ##P < .01, and ###P < .001.
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Figure 9. Characterization
of HSC-specific Sirt6
knockout mice. (A) Western
blot analysis of Sirt6 protein
in primary hepatocytes
(HEPs), HSCs, and Kupffer
cells (KCs) from WT and
HSC-KO mice. (B–D) Immu-
nofluorescence analysis of
Sirt6 and cell-type–specific
markers in HSCs, hepato-
cytes, and KCs isolated from
WT and Lrat–Cre–mediated
HSC-KO mice (n ¼ 5, 3- to
4-month-old males). (E–G)
Measurements of body and
liver weights of WT and
HSC-KO male mice (n ¼ 5).
Data are presented as
means ± SEM. **P < .01 and
***P < .001.
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1.25% cholesterol (by weight), and 0.5% sodium cholate (by
weight), and treated mice for 4 to 8 weeks. On this diet, Sirt6
KO mice developed the NASH phenotype more rapidly than
with the high-fat, high-fructose diet used by the Park group.20
Another reason why we chose to treat the WT and KO mice
for 4 to 8 weeks but not much longer is because hepatic Sirt6
gene expression is down-regulated rapidly by the NASH diet
in WT mice. This down-regulation of Sirt6 diminishes the
gene knockout effect in the long term.
TGFb is thought to be the most potent cytokine for the
induction of hepatic fibrosis.3 Although the canonical
TGFb–SMAD3 pathway has been well established, the
mechanism of epigenetic regulation of SMAD3 activity re-
mains incompletely understood, especially in HSCs. Previous
reports have suggested that SIRT6 modulates the
TGFb–SMAD3 pathway23–25; however, HSC-specific SIRT6
function has not been investigated before. Our data suggest
that SIRT6 is a key regulator of the SMAD3 transcriptional
activity through deacetylation of SMAD3 and histone H3
lysine 9 in HSCs. SMAD3 can be acetylated at multiple lysine
residues by p300/CREB binding protein (CBP).5,45 Our data
have shown that K333 and K378 of SMAD3 are major sub-
strates of SIRT6. Deacetylation of either of them by SIRT6 has
a significant negative effect on the SMAD3 transcriptional
activity. Because the SMAD3 acetylation analysis was per-
formed under Sirt6 gain-of-function and loss-of-function
conditions, additional physiological conditions may be
considered in future studies.
An excessive accumulation of hepatic lipids is believed to
cause liver injury. This is also the case in animals with
chronic WD feeding. Hepatic injury can trigger inflamma-
tion, as manifested by the increased numbers of macro-
phages and neutrophils in the Sirt6-deficient mouse livers.
As a result, a number of inflammatory cytokine and che-
mokine genes, including TNFa, TGFb, IL1b, Ccl2, and Ccl5,
are activated. The resultant inflammatory microenviron-
ment stimulates conversion of quiescent HSCs to activated
HSCs (also known as myofibroblasts). The activated myofi-
broblasts produce excess collagen molecules to cause
fibrosis. In addition, SIRT6-deficient myofibroblasts also
lose the control of TGFb gene regulation. This reinforces the
vicious cycle of TGFb/ TGFb receptor/ SMAD3/ TGFb.
The complete reversal of NASH in our Tg mice suggests
that SIRT6 is a useful therapeutic target for NASH. Because
the Sirt6 Tg mice used in this study were generated using
the ubiquitous cytomegalovirus-Cre, additional character-
ization of other cell types in the liver including liver sinu-
soidal endothelial cells, cholangiocytes, Kupffer cells, andFigure 10. (See previous page). HSC-specific Sirt6 KOmice d
Sirius Red, and Col1 staining and quantification of liver sections
with a WD for 4 weeks. (C) Serum ALT measurements of WT an
Real-time PCR analysis of selected genes in primary HSCs from
month-old males). (E) Real-time PCR analysis of selected gene
weeks. (F and G) Smad3 and p-Smad3 analyses (immunoblotting
male mice fed with a WD for 4 weeks and primary HSCs from
presented as means ± SEM. *P < .05, **P < .01, and ***P <
phospho-SMAD family member 3.macrophages is needed to fully understand the cell-type-
–specific role of Sirt6 in the protection against NASH.
In summary, our data suggest that Sirt6 plays a critical
role in HSCs by modulating the SMAD3 activity and histone
H3 acetylation. Hepatic Sirt6 deficiency poses a high sus-
ceptibility to diet-induced NASH development. Modulation




All animal procedures performed in this work were
approved by the Institutional Animal Care and Use Commit-
tee of Indiana University School of Medicine in accordance
with the National Institutes of Health guidelines for the care
and use of laboratory animals. Liver-specific Sirt6 KO mice
were generated by crossing Sirt6 floxed mice with albumin-
Cre Tg mice as previously described.8,9,46 Inducible hepatic
Sirt6 gene knockout also was generated by crossing the Sirt6
floxed mice with Mx1-Cre transgenic mice from the Jackson
Laboratory (Bar Harbor, ME).47 We confirmed the efficiency
of deletion of the floxed Sirt6 coding sequence in the
Sirt6f/f:Mx1-Creþ/- mouse liver after 3 intraperitoneal in-
jections of polyinosinic:polycytidylic acid every other day,
which induces an interferon response to activate expression
of the Cre recombinase under the Mx1 gene promoter. The
induced ablation of hepatic Sirt6 was nearly complete 10
days after the last polyinosinic:polycytidylic acid injection.
Sirt6 HSC-KO mice were generated by crossing the Sirt6
floxed mice with Lrat-Cre mice.48 Sirt6 global Tg mice were
generated by crossing an inducible Sirt6 Tg mouse carrying a
floxed transcriptional/translational stop (STOP) cassette at
the Rosa 26 locus with a cytomegalovirus-Cre transgenic
mouse from the Jackson Laboratory.49 Animals were fed
either a control diet (Teklad Diets 2018SX: 24% calories from
protein, 18% calories from fat, and 58% calories from car-
bohydrate, Indianapolis, IN), or a WD (Research Diets
D12109C, 20% calories from protein, 40% calories from fat,
40% calories from carbohydrate, and 1.25% cholesterol and
0.5% sodium cholate by weight, New Brunswick, NJ). Both
males and females were used in the experiments and they
were on the mixed background (C57BL/6J and 129/sv). At
the end of the experiments, the animals were killed for blood
and tissue collection.
Human Liver Specimens
Human liver samples were obtained from diagnosed
NASH patients and control subjects. Paraffin-embeddedevelop NASH. (A and B) H&E, myeloperoxidase (MPO), F4/80,
of WT and HSC-KO mice (n ¼ 5, 3- to 4-month-old males) fed
d HSC-KO male mice fed with a WD for 4 weeks (n ¼ 5). (D)
WT and HSC-KO mice fed with a WD for 10 days (n ¼ 3, 3-
s in livers from WT and HSC-KO mice fed with a WD for 4
or fluorescence microscopy) in the livers of WT and HSC-KO
WT and HSC-KO mice fed with a WD for 10 days. Data are
.001 vs WT. DAPI, 40,6-diamidino-2-phenylindole; p-Smad3,
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Figure 11. (See previous page). SIRT6 suppresses the TGFb–SMAD3 pathway in HSCs. (A) Western blot analysis and
quantification of SMAD3 and p-SMAD3 in LX-2 cells that were transduced with adenoviral GFP or SIRT6 shRNA (sh-GFP or
sh-SIRT6) in the absence or presence of TGFb1 (5 ng/mL) for 24 hours. (B) Western blot analysis and quantification of SMAD3
and p-SMAD3 in LX-2 cells that were transduced with adenoviral GFP or SIRT6 (AdGFP or AdSIRT6) in the absence or
presence of TGFb1 (5 ng/mL) for 24 hours. (C and D) Real-time PCR analysis of selected fibrosis genes in LX-2 cells that were
transduced with adenoviral sh-GFP, sh-SIRT6, AdGFP, or AdSIRT6 in the absence or presence of TGF-b1 (5 ng/mL) for 24
hours. (E and F) Western blot analysis of SMAD3 and p-SMAD3 and real-time PCR analysis of selected fibrosis genes in LX-2
cells that were transfected with wild-type SIRT6, SIRT6 (H133Y) mutant, or GFP in the presence of TGFb1 (5 ng/mL) for 24
hours. Data are presented as means ± SEM. *P < .05, **P < .01, and ***P < .001 for TGFb1 treatment vs control for the same
protein or gene; #P < .05, ##P < .01, and ###P < .001. ACTN, actinin; AdGFP, adenoviral green fluorescent protein; GFP, green
fluorescent protein; p-SMAD3, phospho-SMAD family member 3.
Figure 12. SIRT6 interacts with SMAD3 in hepatic stellate cells. (A and B) Co-immunoprecipitation analysis of interactions
between the endogenous SIRT6 and SMAD3 or p-SMAD3 in LX-2 cells in the presence of TGFb1 (5 ng/mL) for 24 hours. (C)
Co-immunoprecipitation analysis of interactions between Sirt6 and Smad3/p-Smad3 in the livers of Sirt6 transgenic mice fed
with a WD for 4 weeks. (D) Immunofluorescence microscopy of SIRT6 and SMAD3 in LX-2 cells in the absence or presence of
TGFb1 (5 ng/mL) for 3 hours. (E) Immunofluorescence microscopy of SIRT6 and p-SMAD3 in LX-2 cells in the presence of
TGFb1 (5 ng/mL) for 3 hours. Ab, antibody; DAPI, 40,6-diamidino-2-phenylindole; Flag, FLAG tag; HA, hemagglutinin; IP,
immunoprecipitation; PCNA, proliferating cell nuclear antigen; p-SMAD3, phospho-SMAD family member 3.
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Table 1.Demographic and Pathologic Characteristics of Patients With NASH
ID Age, y Sex Steatosis Ballooning Lobular inflammation NAS score
1 68 F 1 2 2 5
2 49 F 1 2 1 4
3 56 M 1 2 1 4
4 51 F 2 1 1 4
5 58 F 3 1 1 5
6 56 M 2 1 1 4
7 48 F 3 1 1 5
8 57 F 2 1 1 4
9 62 F 1 2 1 5
10 53 F 2 2 1 5
11 44 F 1 0 1 2
12 64 M 1 0 1 2
NAS, NAFLD activity score.
358 Zhong et al Cellular and Molecular Gastroenterology and Hepatology Vol. 10, No. 2liver sections from patients with simple steatosis and
different stages of fibrosis by histopathologic diagnosis of
NASH were obtained under the institutional review
board–approved protocol at the Indiana University–Purdue
University Indianapolis. General characteristics of the NASH
patients are described in Table 1.
Plasmid Constructs and Adenoviral Vectors
Human SIRT6 and SIRT6 H133Y mutant (catalytically
inactive) and green fluorescent protein (GFP) coding se-
quences were cloned into a pcDNA3 plasmid vector (Invi-
trogen, Carlsbad, CA) with a FLAG epitope or hemagglutinin
(HA) epitope tag. SIRT6 and GFP overexpression adenovi-
ruses were prepared in an AdEasy adenoviral vector system
(Agilent, Santa Clara, CA) following the manufacturer’s
manual. SIRT6 and GFP shRNA adenoviruses were made
using a BLOCK-iT system (Invitrogen). Human SMAD3
lysine acetylation sites were mutated using a Q5 site-
directed mutagenesis kit (New England Biolabs, Ipswich,
MA). DNA oligonucleotides used in this work are described
in Table 2. The recombinant DNA work was approved by the
Indiana University Institutional Biosafety Committee.
Cell Culture, Plasmid Transfection, and
Adenoviral Transduction
Human hepatic stellate cell line LX-2 (MilliporeSigma,
Burlington, MA) was cultured in Dulbecco’s modified EagleFigure 13. (See previous page). SIRT6 attenuates the SMAD3
acetylation and phosphorylation and quantification analysis in LX
shRNA (sh-Sirt6) sh-Sirt6, or green fluorescent protein shRNA
t6_H133Y mutant, or GFP plasmids. (C) ChIP-PCR analysis of c
regions in LX-2 cells in the presence of TGFb1 (5 ng/mL) for 24
H3K9Ac, or IgG control. The chromatin binding activity of SIRT6
input DNA amount. (D and E) Western blot analysis of deacety
analysis of the deacetylation effect on fibrosis genes in LX-2 ce
and ***P < .001 vs (A) control or GFP, (C) PPIA-non-specific (NS
###P < .001. Ad, adenoviral; Flag, FLAG tag; IP, immunopre
member 3.medium (DMEM) (Thermo Fisher Scientific, Waltham, MA)
supplemented with 2% fetal bovine serum and penicillin/
streptomycin (Thermo Fisher Scientific). For adenoviral
transduction, we used a multiplicity of infection of 20 for
overexpression and a multiplicity of infection of 100 for
shRNA knockdown experiments. Mouse primary cells were
isolated from WT, Sirt6-KO (Alb-Cre), Sirt6-KO (Mx1-Cre),
and HSC-KO (Lrat-Cre) mice. Hepatocytes, Kupffer cells, and
HSCs were isolated as previously described.50 Experiments
were performed from 3–4 mice per genotype. To set up co-
culture of hepatocytes and HSCs, freshly isolated primary
mouse hepatocytes were seeded in a Transwell insert at
0.5  106/well with DMEM plus 10% fetal bovine serum,
and primary mouse HSCs were seeded in a well of a
Transwell plate at 0.5  106/well with DMEM plus 10%
fetal bovine serum.Real-Time PCR Analysis
Total RNAs were isolated from cells or tissues using the
TRI reagent (MilliporeSigma) and converted into comple-
mentary DNA using a complementary DNA synthesis kit
(Applied Biosystems, Foster City, CA). Real-time PCR
analysis was performed using SYBR Green Master Mix
(Promega, Madison, WI) in an Realplex PCR system
(Eppendorf North America, Hauppauge, NY). Transcript
levels were analyzed with the 2delta delta cycle threshold
method, and quantification was normalized to the internaltranscriptional activity via deacetylation. (A and B) SMAD3
-2 cells either transduced with adenoviral Sirt6 (AdSirt6), Sirt6
(shGFP) adenoviruses, or transfected with SIRT6_WT, Sir-
hromatin binding of SIRT6 and SMAD3 in the indicated gene
hours using specific antibodies against SIRT6, SMAD3, and
, SMAD3 and H3K9Ac is presented as the percentage of the
lation of WT or mutant SMAD3 by SIRT6 and real-time PCR
lls. Data are presented as means ± SEM. *P < .05, **P < .01,
), or (E) vector for the same SMAD3 genotype; ##P < .01 and
cipitation; Pro, promoter; p-SMAD3, phospho-SMAD family
Table 2.DNA Oligonucleotide Sequences
Name Sequence
Mouse Sirt6 qPCR Forward: 5’-ACGTCAGAGACACGGTTGTG-3’
Reverse: 5’-CCTCTACAGGCCCGAAGTC-3’
Mouse Tnf qPCR Forward: 5’-GGCCTCCCTCTCATCAGTTC-3’
Reverse: 5’-CACTTGGTGGTTTGCTACGA-3’
Mouse Il1b qPCR Forward: 5’-TGTGAAATGCCACCTTTTGA-3’
Reverse: 5’-GGTCAAAGGTTTGGAAGCAG-3’
Mouse Col1a1 qPCR Forward: 5’-CACCTGGTCCACAAGGTTTC-3’
Reverse: 5’-CCCATCATCTCCATTCTTGC-3’
Mouse Col3a1 qPCR Forward: 5’-TGCTGGAAAGGATGGAGAGT-3’
Reverse: 5’-TGGGCCTTTGATACCTGGAG-3’
Mouse Col4a1 qPCR Forward: 5’-TTCGCCTCCAGGAACGACTA-3’
Reverse: 5’-AAACCGCACACCTGCTAATG-3’
Mouse Acta2 qPCR Forward: 5’-AGGCACCACTGAACCCTAAG-3’
Reverse: 5’-GACAGCACAGCCTGAATAGC-3’
Mouse Tgfb1 qPCR Forward: 5’-CGCAACAACGCCATCTATGA-3’
Reverse: 5’-ACTGCTTCCCGAATGTCTGA-3’
Mouse Timp1 qPCR Forward: 5’-CATGGAAAGCCTCTGTGGAT-3’
Reverse: 5’-CTCAGAGTACGCCAGGGAAC-3’
Mouse Tgfbr1 qPCR Forward: 5’-TTCCTCGAGACAGGCCATTTG-3’
Reverse: 5’-CAGCTGACTGCTTTTCTGTAGT-3’
Mouse Ccl2 qPCR Forward: 5’-CCCAATGAGTAGGCTGGAGA-3’
Reverse: 5’-TCTGGACCCATTCCTTCTTG-3’
Mouse Ccl5 qPCR Forward: 5’-GTGCCCACGTCAAGGAGTAT-3’
Reverse: 5’-CTCTGGGTTGGCACACACTT-3’
Mouse Il6 qPCR Forward: 5’-CAAAGCCAGAGTCCTTCAGAG-3’
Reverse: 5’-GAGCATTGGAAATTGGGGTA-3’
Mouse Arg1 qPCR Forward: 5’-CAAGACAGGGCTCCTTTCAG-3’
Reverse: 5’-TGAGTTCCGAAGCAAGCCAA-3’
Mouse Il10 qPCR Forward: 5’-CAGAGCCACATGCTCCTAGA-3’
Reverse: 5’-GCTTGGCAACCCAAGTAACC-3’
Human COL1A1 qPCR Forward: 5’-CCCGAGGCTCTGAAGGTC-3’
Reverse: 5’-GAGCACCATTGGCACCTTT-3’
Human COL3A1 qPCR Forward: 5’-GCAGGGTCTCCTGGTTCAAA-3’
Reverse: 5’-CGGGACCCATTTCGCCTTTA-3’
Human ACTA2 qPCR Forward: 5’-CCGGGACTAAGACGGGAATC-3’
Reverse: 5’-TTGTCACACACCAAGGCAGT-3’
Human TIMP1 qPCR Forward: 5’-TTTTGTGGCTCCCTGGAACA-3’
Reverse: 5’-AAACAGGGAAACACTGTGCAT-3’
Human SMAD3 K333R mutation PCR Forward: 5’-ACCGTCTGCAGGATCCCACCAGG-3’
Reverse: 5’-GGCCGGGTGCCAGCCATA-3’
Human SMAD3 K378R mutation PCR Forward: 5’-AGCTTCGTCAGAGGCTGGGGA-3’
Reverse: 5’-CATGCGGATGGTGCACATTC-3’
Human TGFB1 gene promoter ChIP PCR Forward: 5’-ACGTCAGAGACACGGTTGTG-3’
Reverse: 5’-AGGGTGTCAGTGGGAGGA-3’
Human COL1A2 gene promoter ChIP PCR Forward: 5’-ACTCCGACGTGTCCCATAGTG-3’
Reverse: 5’-GGCTGGCTTCTTAAATTGGTTCCA-3’
Human PPIA gene promoter ChIP PCR Forward: 5’-CTAAAGCGCCAGGTATGAGCA-3’
Reverse: 5’-GCGAATTTCTTCAGGCAAAG-3’
Human COL1A2 gene exon ChIP PCR Forward: 5’-CCATCACGCCTGCCCTTC-3’
Reverse: 5’-CAGACTGGGCCAATGTCCAC-3’
Human SIRT6 AdEasy primers Forward: 5’-CTTCCGATATCGCCACCATGTCGGTGAATTACGCGGC-3’
Reverse: 5’-AAGGAACTCGAGGCTGGGGACCGCCTTG-3’
Human SIRT6 shRNA target 5’-GCTACGTTGACGAGGTCATGA-3’
GFP control shRNA 5’-GCATCAAGGTGAACTTCAAGA-3’
qPCR, quantitative polymerase chain reaction.
2020 SIRT6 Function in Hepatic Fibrosis 359
Table 3.Antibody information
Antibody Source Catalog Number Application





Sirt6 Sigma, St. Louis, MO S4197 IF: 1:200
Sirt6 Novus, Centennial, CO NB1002522 IF: 1:200
Sirt6 Invitrogen, Waltham, MA MA5-24768 IF: 1:200
a-Actinin Santa Cruz Biotechnology,
Dallas, TX
sc-17829 WB: 1:10000




Phospho-Smad3 (Ser423/425) Cell Signaling Technology 9520S WB: 1:1000
IF: 1:200
IP: 1 mg
Anti-HA agarose Thermo Fisher Scientific,
Waltham, MA
26181 IP: 20 mL
Anti-Flag gel Sigma A2220 IP: 20 mL
Protein A/G Plus Agarose Santa Cruz Biotechnology Sc-2003 IP: 20 mL
Anti-HA Cell Signaling Technology 3724S WB: 1:3000
FoxO1 Cell Signaling Technology 2880 WB: 1:1000
PCNA Cell Signaling Technology 2586S WB: 1:1000
E-cadherin Cell Signaling Technology 3195S WB: 1:1000
Vimentin Cell Signaling Technology 5741S WB: 1:1000
Desmin Thermo Fisher Scientific RB-9014-P WB: 1:1000
IF: 1:100
Desmin DSHB, Iowa City, IA D3 IF: 1:25
CK-19 DSHB TROMA-III IF: 1:25
Albumin Santa Cruz Biotechnology Sc-271605 WB: 1:1000
IF: 1:100
Smad2 Cell Signaling Technology 5339S WB 1:1000
Phospho-Smad2 (Ser465/467) Cell Signaling Technology 18338S WB: 1:1000
Anti-Flag Sigma F1804 WB: 1:3000
Sirt1 Cell Signaling Technology 8469S WB: 1:1000
Smad4 Cell Signaling Technology 46535S WB: 1:1000
Acetylated-lysine Cell Signaling Technology 9441L WB: 1:1000
Normal mouse IgG Invitrogen 10400C IP: 1 mg
Normal rabbit IgG Invitrogen 10500C IP: 1 mg
MPO Invitrogen PA516672 IHC: 1:100
F4/80 Invitrogen MA516363 IHC: 1:100
IF: 1:100
Collagen I Abcam, Cambridge, MA ab21286 IF: 1:100
CK-19, cytokeratin 19; Flag, FLAG tag; HA, hemagglutinin tag; IF, immunofluorescence; IHC, immunohistochemistry;
IP, immunoprecipitation; MPO, myeloperoxidase; PCNA, proliferating cell nuclear antigen; WB, Western blotting.
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this work are described in Table 2.
Blood Chemistry and Metabolic Analysis
Lipids were extracted from tissues using a
chloroform–methanol extraction protocol as previously
described.51 Triglyceride measurements were performed
using an L-type triglyceride assay kit (FUJIFILM WakoDiagnostics, Richmond, VA). Serum ALT analysis was per-
formed using an assay kit from Thermo Fisher Scientific.
Immunocytochemistry and
Immunohistochemistry Analysis
Cells were grown in a glass-bottom dish and then fixed
with 4% paraformaldehyde for 15 minutes at room tem-
perature, followed by washing 3 times with phosphate-
2020 SIRT6 Function in Hepatic Fibrosis 361buffered saline (PBS), and incubating overnight with pri-
mary antibodies as described in Table 3. After washing 3
times with PBS, cells were incubated with Alexa
Fluor–conjugated secondary antibodies (1:250; Invitrogen)
for 1.5 hours, followed by counterstaining and mounting
with Prolong Gold antifade mountant with 40,6-diamidino-2-
phenylindole (Invitrogen). Images were taken with a Zeiss
Axio Observer Z1 fluorescent microscope (Zeiss USA,
Thornwood, NY). Liver tissue samples were fixed in 10%
formalin solution and stored in 70% ethanol before they
were processed for embedding and sectioning at the His-
tology Core of Indiana University School of Medicine. Liver
sections were stained with H&E or Sirius Red stain (Milli-
poreSigma). Immunohistochemistry analysis was performed
for myeloperoxidase, F4/80, and other proteins using the
following procedures. Liver sections were deparaffinized
and hydrated in 1mmol/L EDTA buffer for antigen retrieval
at 100C for 5minutes, and the liver sections then were
incubated with normal horse serum for 1 hour. Next, the
liver sections were incubated with primary antibodies
described in Table 3 at 4C overnight. After they were
washed with PBS containing 0.05% Tween-20, the liver
sections were incubated with either a biotinylated universal
pan-specific antibody included in a Vectastain ABC kit from
Vector Laboratories (Burlingame, CA) or fluorophore-
conjugated secondary antibody for 2 hours. The sections
incubated with the biotinylated antibody subsequently were
incubated with avidin–biotin peroxidase complexes (Vector
Laboratories) for 1 hour. Peroxidase activity was detected
using diaminobenzidine solution (Vector Laboratories). Im-
ages were taken using a regular microscope (original
magnification, 100 or 200; Leica, Buffalo Grove, IL) or a
fluorescent microscope (original magnification, 200,
400, or 630; Zeiss USA). Quantification of the images was
performed from randomly selected sections of at least 5
fields of each sample using ImageJ software (version 1.52;
National Institutes of Health, Bethesda, MD).Western Blot and Immunoprecipitation Analyses
Immunoblotting and immunoprecipitation analyses
were performed as previously described.52 Tissue sam-
ples were homogenized in the lysis buffer (50 mmol/L
HEPES, pH 7.5, 150 mmol/L NaCl, 10% glycerol, 1%
Triton X-100, 1.5 mmol/L MgCl2, 1 mmol/L EDTA, 10
mmol/L sodium pyrophosphate, 100 mmol/L sodium
fluoride, and freshly added 100 mmol/L sodium vana-
date, 1 mmol/L phenylmethylsulfonyl fluoride, and 1
cOmplete protease inhibitor cocktail [Roche, Indian-
apolis, IN]). Cell lysates were prepared in the NP-40
lysis buffer (1% NP-40, 20 mmol/L Tris, pH 7.4, 137
mmol/L NaCl, 2 mmol/L EDTA, 10% glycerol, 1 mmol/L
phenylmethylsulfonyl fluoride, and 1 cOmplete prote-
ase inhibitor cocktail). Protein samples were resolved by
sodium dodecyl sulfate–polyacrylamide gel electropho-
resis and transferred to a nitrocellulose membrane for
immunoblotting analysis using specific antibodies.
Enhanced chemiluminescence signals on Western blot
were analyzed by Gelpro32 Software (Media Cybernetics,Marlow, UK) for quantitative analysis. For immunopre-
cipitations, equal amounts of protein extracts were
incubated with 1 mg of specific antibodies for 16 hours
at 4C. Protein A/G plus agarose beads (Santa Cruz
Biotechnology, Dallas, TX) then were added for a 3-hour
incubation at 4C. Normal rabbit or mouse IgG was used
as a negative control. Immunoprecipitated proteins were
analyzed by immunoblotting. Antibodies used in this
work are described in Table 3.ChIP
Chromatin association analysis was performed in LX-2
cells by chromatin preparation as previously described,9
immunoprecipitation with antibodies against Sirt6 (Milli-
poreSigma, St. Louis, MO), Smad3 (Cell Signaling Technol-
ogy, Danvers, MA), and H3K9Ac (Cell Signaling Technology),
and real-time PCR analysis. ChIP DNA amounts for gene
promoters of interest were normalized to the input DNA for
the same gene sequence. Primers used in the ChIP PCR re-
actions are described in Table 2.Statistical Analysis
All statistical data are expressed as means ± SEM. Sta-
tistical analysis was performed using Prism 8 software from
GraphPad (La Jolla, CA). Comparisons between 2 groups
were performed using a 2-tailed Student t test and com-
parisons for more than 2 groups were performed using 1-
way analysis of variance followed by the Tukey post hoc
test.
All authors had access to the study data and reviewed
and approved the final manuscript.References
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